Merus Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This Merus Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP tests for recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 22 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply a usable record and must not be read as evidence of absence.
Executive BD thesis
Merus is screened as a potential partnering counterparty across asset licensing, regional commercialization, co-development, platform access and evidence-generation structures. The organization pipeline call returned 12 records at the decision date. The lead returned asset is Zenocutuzumab-zbco, associated with HER2 x HER3 and NRG1 gene fusion cholangiocarcinoma, Adenocarcinoma of pancreas with NRG1 fusion, NRG1 Fusion Positive non-small cell lung cancer, ER Positive/HER2 Low Breast Cancer, at Approved. The immediate objective is to identify a narrow, executable right set and the evidence package required to test strategic fit.
A high-quality first meeting should confirm the current development owner, decision rights, territory availability, stage definitions, program status, patent ownership, third-party licenses, CMC readiness, clinical evidence, regulatory history and management’s preferred transaction structure. Pipeline size is a starting signal, not a substitute for strategic fit or diligence.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | Zenocutuzumab-zbco | Merus NV | Approved | Pipeline record: HER2 x HER3; NRG1 gene fusion cholangiocarcinoma, Adenocarcinoma of pancreas with NRG1 fusion, NRG1 Fusion Positive non-small cell lung cancer, ER Positive/HER2 Low Breast Cancer. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Genmab A/S acquires Merus NV | Approved asset with HER2 x HER3 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
| 2 | Petosemtamab | Merus NV | Phase 2 | Pipeline record: EGFR x LGR5; Advanced Malignant Solid Neoplasm, Esophageal Carcinoma, Gastrooesophageal junction cancer, Metastatic Colorectal Carcinoma. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs | Phase 2 asset with EGFR x LGR5 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
| 3 | MCLA-145 | Merus NV | Phase 1 | Pipeline record: 4-1BB x PDL1; Advanced cancer, Advanced Malignant Solid Neoplasm, B-Cell Lymphoma, Metastatic Solid Tumor. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer | Phase 1 asset with 4-1BB x PDL1 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
| 4 | Besufetamig | Merus NV | Phase 1 | Pipeline record: CD3 x PD-1; Psoriasis. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Genmab A/S acquires Merus NV | Phase 1 asset with CD3 x PD-1 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
| 5 | Pamvatamig | Merus NV | Phase 1 | Pipeline record: EGFR x c-Met; Solid tumor. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs | Phase 1 asset with EGFR x c-Met exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
Shortlist interpretation. Priority one should receive the fastest outreach only after the returned owner and stage are reconfirmed. Lower-ranked rows preserve option value and may support a regional license, co-development collaboration, asset carve-out, structured option, research partnership or financing-linked agreement. Any mismatch among asset name, owner, indication and stage is itself a diligence signal that may reflect a transfer, dormant program, territory split or portfolio reprioritization.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage when those fields are returned. Reconcile them against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, subgroup results, safety narratives, manufacturing comparability, stability data, health-authority feedback and the sponsor’s integrated development plan.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across the company record, trial registries and regulatory sources. A stage label should be translated into a milestone map with dates, endpoints, decision gates and remaining cost. Where the MCP result is missing or ambiguous, do not fill the gap by assumption: make the refresh and reconciliation an explicit condition before valuation.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2025-09-29 | Genmab A/S acquires Merus NV | Completed | Not disclosed |
| 2025-01-12 | Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs | Active | Not disclosed |
| 2024-12-02 | Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer | Active | Not disclosed |
Transaction precedents guide structure rather than mechanically determine price. Normalize every comparison for stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones, sublicensing, governance, termination and change-of-control provisions. Undisclosed economics can still reveal counterparties, strategic intent and preferred transaction form. A missing search result should trigger a broader licensor/licensee and asset-level search before negotiation.
Financial capacity and partnering pressure
- Merus N.V. - 2023 Annual report: Merus N.V. - 2023 Annual report PART II Based on our current operating plan, research and development plans and our timing expectations related to the progress of our programs, we expect that our existing cash, cash equivalents and marketable securities as of December 31, 2023, will be sufficient to fund our planned operating expenses and capital expenditure requirements into 2027. We have based this estimate on assumptions that may prove to be wrong, particularly as the process of testing product candidates in clinical trials is costly and the timing of progress in these trials is uncertain. As a result, we could use our capital resources sooner than we expect. Cash Flows The following is a summary of cash flows for the years ended December 31, 2023 and 2022: Operating Activities Net cash used in operating activities for the year ended December 31, 2023 decreased $7.7 million as compare
- Merus N.V. - 2025 Quarterly report: Merus N.V. - 2025 Quarterly report Sources of Cash As of March 31, 2025, we had $638.2 million in cash, cash equivalents and marketable securities that are available to fund our current operations. Our cash and cash equivalents are maintained at financial institutions in amounts that exceed federally insured limits. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurances that we will be able to access uninsured funds in a timely manner or at all. In addition to our existing cash, cash equivalents and marketable securities, we may receive research and development co-funding and are eligible to earn a significant amount of milestone payments under our collaboration agreements and research license agreements. Our ability to earn these payments and the timing of earning these payments is dependent upon the outco
- Merus N.V. - 2020 Annual report: Merus N.V. - 2020 Annual report RISK FACTORS Collaborations and Other Revenue Generating Agreements Refer to Item 1, “Business—Our Collaborations” and Note 12, “Collaborations,” of the notes to our Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K for a description of Results of Operations for the Years Ended December 31, 2020 and 2019 Revenue The following is a comparison of collaboration revenue for the years ended December 31, 2020 and 2019: Our revenue from each collaboration partner consists of revenue recognized from the amortization of deferred revenue related to upfront payments for licenses or options to obtain licenses in the future, research and development services reimbursement revenue earned and milestone payments earned under collaboration and license agreements with our collaboration partners. Collaboration revenue for the year ended
Translate financial signals into BD questions. Confirm unrestricted cash, quarterly operating use, committed trials, debt and royalty financing, covenant constraints, near-term milestone receipts, commercial investment and management’s minimum runway threshold. A well-capitalized company may prefer a premium strategic collaboration; a constrained company may prioritize non-dilutive funding, regional monetization, cost sharing or a staged option.
Current-awareness events and outreach triggers
The Current Awareness news_search call did not return a parseable recent-event record at the decision date. Refresh the search before outreach and reconcile press releases, trial updates, regulatory events, financing announcements, management changes and partnering disclosures. Do not interpret the missing return as absence of news.
The best outreach window often follows a data readout, regulatory interaction, financing, portfolio review, leadership change or new transaction. Build a trigger calendar and identify the person who owns the asset, the therapeutic-area BD lead, the regional commercial lead and alliance-management stakeholders. Outreach should cite one verified event and one specific contribution the prospective partner can make.
IP and freedom-to-operate risk screen
The IP review is a gating workstream, not a footnote. Request the full patent-family schedule, inventorship and assignment history, prosecution status, expected expiries, patent-term adjustment or extension assumptions, opposition and litigation history, third-party licenses, field and territory restrictions, royalties, reach-through clauses, government rights and material-transfer obligations. Map composition-of-matter, method-of-use, formulation, manufacturing, biomarker, combination, platform and delivery claims to the exact rights proposed in the deal.
Screen risk as medium by default when an asset and owner are returned but the patent package has not been reviewed; elevate it to high where ownership, stage or program status is not returned. A license must match patents, know-how, data, regulatory references, materials, manufacturing rights and sublicensing rights to the precise field and geography. Complete a claim-level patent and FTO review before exclusivity, valuation or term-sheet approval.
Recommended deal structures
- Regional license: useful when development or commercial capabilities differ by territory; define data access, regulatory responsibilities, supply, transfer pricing and reversion rights.
- Co-development: appropriate when both parties contribute clinical, biomarker, regulatory or commercial capabilities; specify cost sharing, governance, global strategy and opt-out economics.
- Option-to-license: reduces uncertainty before a defined data event; specify option fee, exercise trigger, diligence standard, exclusivity period and pre-agreed economics.
- Research or platform collaboration: suitable when the value resides in discovery or delivery capability; define targets, ownership of foreground IP, publication, replacement rights and downstream options.
- Structured financing: may combine equity, milestone funding, royalties or territory monetization; test covenant, accounting, control and change-of-control implications.
Outreach rationale and first-contact plan
- Identify the decision owner. Map the asset team, corporate-development lead, therapeutic-area leadership, regional commercial lead and alliance-management stakeholders.
- Lead with one verifiable gap. Focus on territory, evidence, diagnostics, manufacturing, delivery, financing or combination strategy rather than a generic partnership request.
- Attach a concise evidence package. Include the returned stage, indication footprint, relevant transaction precedent, partner contribution, proposed work plan and decision gates.
- Offer a structure. Present one primary and one fallback structure with clear rights, funding, governance and diligence assumptions.
- Define the diligence sequence. Request data-room access, IP/FTO materials, CMC documents, safety data, regulatory correspondence, economics and encumbrances before exclusivity.
Decision memo
ADVANCE TARGETED OUTREACH, SUBJECT TO EVIDENCE REFRESH. Merus offers a credible screening case because the MCP workflow identifies either a returned pipeline opportunity or a concrete set of evidence gaps that can be tested rapidly. The first contact should be tailored to a named asset where available, quantify the partner’s contribution, acknowledge IP and execution risks and avoid using pipeline count as a proxy for value.
Required next diligence: refresh all four MCP searches; fetch full deal records for economics and rights; reconcile the newest financial filing and public event disclosures; verify owner and license chain; obtain patent-family and FTO work; review CMC, safety and regulatory materials; and model risk-adjusted economics by indication, territory and transaction structure.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
Data provenance: PatSnap Company & Deal Intelligence MCP (organization_pipeline_fetch, drug_deal_search, financial_report_search) and Current Awareness MCP (news_search); accessed 22 July 2026. Counts, ownership and statuses may change as records update.
